19th Dec 2019 16:27
(Alliance News) - Oxford Biomedica PLC said Thursday it has extended a commercial supply agreement by five years for the manufacture of lentiviral vectors for the Novartis CAR-T portfolio.
The gene and cell therapy group said this agreement extension builds on the existing three-year commercial supply agreement signed by the parties in July 2017.
Under the terms of the agreement, Oxford Biomedica will receive a minimum USD75 million from Novartis AG over the next five years in manufacturing revenue with additional undisclosed process development fees.
Oxford Biomedica said it will dedicate a manufacturing facility to the Novartis work within its new 7,800 square metre commercial manufacturing centre OxBox, in Oxford.
The company will also be responsible for ensuring at least two of its good manufacturing practice facilities are capable of commercial supply for Novartis' CAR-T programmes.
John Dawson, chief executive officer of Oxford BioMedica, said: "This closely integrated collaboration with Novartis underlines the long-term committent both companies have made to manufacturing CAR-T therapies."
Oxford Biomedica shares were up 0.9% in London at 637.35 pence each on Thursday.
By Loreta Juodagalvyte; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica